Posted by Michael Wonder on 18 Oct 2023
Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder
18 October 2023 - Approval exemplifies commitment to broadening access for patients living with rare diseases globally.
Soliris (eculizumab) has been approved in China for the treatment of adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.
